Firma immatics biotechnologies, Autor bei News-Blast

Der erste Patient in Deutschland wurde im Rahmen der Immatics‘ ACTengine® IMA202-101 Studie behandelt Die deutsche Zulassungsbehörde, das Paul-Ehrlich-Institut (PEI), hat den Antrag (CTA, Clinical Trial Application) für eine weitere klinische ACTengine®-Studie in Deutschland genehmigt. Die Studie wird Immatics‘ Produktkandidaten IMA203 untersuchen Drei klinische Studienzentren haben in Deutschland mit der Patienten-Rekrutierung für Immatics‘ ACTengine®-IMA200-Studienprogramme begonnen […]

Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs

18. August 2020

Forschung und Entwicklung Firma immatics biotechnologies

First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trial German regulatory agency, Paul-Ehrlich-Institute (PEI), granted approval to commence another clinical ACTengine® trial in Germany investigating Immatics’ IMA203 product candidate Three clinical trial sites in Germany have started recruiting patients for Immatics’ ACTengine® IMA200 trial series Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage […]

Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth

6. August 2020

Forschung und Entwicklung Firma immatics biotechnologies

. Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to state-of-the art cGMP manufacturing infrastructure at The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory Collaboration ensures continued clinical batch supply for all of Immatics’ ongoing and next Adoptive Cell Therapy (ACT) clinical trials in US and Europe […]

Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ

9. Juli 2020

Forschung und Entwicklung Firma immatics biotechnologies

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced changes to its Board of Directors in conjunction with its recent listing on NASDAQ. Michael Atieh, Paul Carter, Heather Mason and Adam Stone will join the Company’s board as new members. Christof Hettich, […]

Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics

30. Juni 2020

Kooperationen / Fusionen Firma immatics biotechnologies

Arya Sciences Acquisition Corp. (NASDAQ: ARYA or “Arya”), a special purpose acquisition company sponsored by Perceptive Advisors, and Immatics Biotechnologies GmbH (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced that its respective shareholders approved the business combination between Arya and Immatics announced on March […]

Immatics Appoints Cedrik Britten as Chief Medical Officer

4. Juni 2020

Allgemein Firma immatics biotechnologies

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced that Cedrik Britten, MD, has been appointed as Chief Medical Officer (CMO) effective June 1, 2020. Trained as a physician, Cedrik Britten will join Immatics with more than a decade of experience in clinical […]